AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02128659 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHE Project
Description: Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
Study NCT04063735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cordyceps Cicadae Mycelia
Description: Cordyceps Cicadae Mycelia supplement for 3 months
Study NCT04063735 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was given to participants.
Study NCT01968187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 992097
Study NCT01968187 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT06478511 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate dental implant placement using socket shield technique
Description: The crown of the involved tooth will be removed and the root will be then sectioned in a mesiodistal direction along its long axis as far apical as was possible using a long shank fissure bur. Preserving the facial root section unmanipulated and attached to the tooth socket. Periotomes will be then inserted between the palatal root removed gentelly.The remaining root section will be then reduced coronally to 1 mm above the alveolar crest.The tooth socket's palatal wall and apex will be then curetted to remove any tissue or infective remnants and the root section will be checked for immobility with a sharp probe. With the preparation steps complete, the tooth root hereafter will be known as the socket-shield. An osteotomy will be then sequentially prepared and internal conical connection implant was inserted palatal to the shield with the implant 2 mm below the facial crest.
Study NCT02156323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMS
Description: Multiple doses of CMS over 2.5 days
Study NCT02156323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877
Description: Multiple doses of RO7033877 over 2.5 days
Study NCT02156323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7033877 + CMS
Description: Multiple doses of RO7033877 and CMS over 2.5 days
Study NCT03412877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day x 2 days IV in 250 mL D5W infused simultaneously with mesna 15 mg/kg/day over 1 hour x 2 days.
Study NCT03412877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
Study NCT03412877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses). Patients in Cohort 3 may receive 72,000 IU/kg IV.
Study NCT03412877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Individual Patient TCR-Transduced PBL
Description: Day 0: Cells will be infused intravenously on the Patient Care Unit over 20-30 minutes (2-4 days after the last dose of fludarabine).
Study NCT03412877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (KEYTRUDA )
Description: Arm 2: Pembrolizumab 2 mg/kg IV over approximately 30 minutes on Days -2, 21, 42, and 63.
Study NCT00118989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcuminoids
Description: Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
Study NCT00118989 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Curcuminoids
Description: Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
Study NCT03011177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin
Description: teneligliptin 20mg qd
Study NCT03011177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: linagliptin 5mg qd
Study NCT00826059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Sphenopalatine Ganglion (SPG) Stimulation
Description: SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
Study NCT00826059 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Sphenopalatine Ganglion (SPG) Stimulation
Description: Sham SPG stimulation and standard of care. During all study periods, patients will receive Standard of Care in accordance to the general management of ischemic stroke and secondary prevention, following the guidelines of the American Heart Association/American Stroke Association and of the European Stroke Organization (ESO), including the use of antiplatelets, management of secondary stroke, dyslipidemia, hypertension, diabetes and counseling regarding smoking cessation. Off-label uses of drugs and devices should not occur during any of the study periods.
Study NCT01116622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bexarotene (Targretin®)
Description: Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
Study NCT01116622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (Tarceva™)
Description: Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
Study NCT03516162 — intervention group
Intervention type: OTHER
Intervention: There is no study-specific intervention
Description: There is no study-specific intervention
Study NCT04587141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial iron
Description: This is an oral iron formulation commercially available as an integrator
Study NCT04587141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Gluconate
Description: This is a commercially available iron formulation for parenteral administration
Study NCT04587141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: This is a commercially available iron formulation for parenteral administration
Study NCT00638469 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: UVB-311nm
Description: UVB-311nm radiation given 3 times a week to one randomized body half
Study NCT00638469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: no UV exposure
Study NCT03476057 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Device： NGS sequencing cfDNA
Description: NGS sequencing cfDNA and Tumor Burden
Study NCT02030119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentives
Study NCT02030119 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily feedback
Study NCT02030119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Study NCT00587691 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tovaxin Autologous T Cell Vaccine
Description: Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.~Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.~Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.
Study NCT00018057 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training
Description: The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
Study NCT00018057 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Attention Bias Modification Training
Description: The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
Study NCT00018057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Randomized assignment.
Study NCT02907398 — intervention group
Intervention type: DEVICE
Intervention: Inspire therapy
Study NCT02907398 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04408755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786
Description: oral capsules
Study NCT04408755 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules
Study NCT03727633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin and Lipiodol
Description: Hepatic intra-arterial chemotherapy consisting of the hepatic intra-arterial injection Idarubicin, emulsified with Lipiodol
Study NCT02868021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Strength testing
Description: Test the strength of subject's lower extremity muscles on the dynamometer system
Study NCT02868021 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Strength testing
Description: Test the strength of subject's lower extremity muscles on the dynamometer system
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Description: The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
Study NCT04666636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one pill (placebo) daily for the first week and two pills daily for the remaining 15 weeks.
Study NCT04666636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Participants will take one pill (50mg Mirabegron) daily for the first week. For week two, participants will take two pills (50mg and 25mg Mirabegron). Unless there are side effects, for the remaining 14 weeks participants will take two pills (50mg each) daily.
Study NCT04417998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-FDG
Description: A cohort of participants in Aim 2 will undergo a 18F-FDG PET/CT scan. This scan is done with a radiotracer called 18F-fluorodeoxyglucose (FDG). FDG looks at cellular activity.
Study NCT04417998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-AV1451
Description: A cohort of participants in Aim 2 will undergo a 18F-AV1451 PET/CT scan. This scan is done with a radiotracer called 18F-AV1451 (TAU) that will find small areas of tau (abnormal protein) in the brain.
Study NCT04417998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Siemens E7 Reconstruction Tool
Description: Software to correct for motion
Study NCT04824079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Keynatinib
Description: The recommended dose is 20 mg Keynatinib twice a day until disease progression， unacceptable toxicity death occurs or withdraw from the study, whichever occurs first.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Short Physical Performance Battery (SPPB)
Description: The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Six-minute walk (SMW)
Description: Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Six-minute walk (SMW)
Description: Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Numerical pain scale
Description: Measure pain using an 11-point numerical pain scale.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Numerical pain scale
Description: Measure pain using an 11-point numerical pain scale.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-assessed function
Description: Using the Late Life Function and Disability Instrument.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-assessed function
Description: Using the Late Life Function and Disability Instrument.
Study NCT02868021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Muscle biopsies
Description: During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
Study NCT02868021 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Muscle biopsies
Description: During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
Study NCT02868021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Determination of 1 Repetition Maximum (1-RM)
Description: Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
Study NCT02868021 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction exercise
Description: Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
Study NCT02868021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Borg CR10 scale
Description: Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
Study NCT01476267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: Single oral radiolabeled dose
Study NCT00642005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fisher and Paykel Humidifier (MR860)
Description: Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
Study NCT00642005 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard insufflation
Description: No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
Study NCT04382716 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention; observation only
Study NCT03646747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Additional imaging using MRI scan
Study NCT02213380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: method of anesthesia
Description: General anesthesia and regional anesthesia.~General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.~Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA
Study NCT00905632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 middle dose +SOC
Description: BI 207127 middle dose tid + SOC
Study NCT00905632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 high dose+SOC
Description: BI 207127 high dose tid +SOC
Study NCT00905632 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + SOC
Description: Placebo tid +SOC
Study NCT00905632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127 low dose + SOC
Description: BI 207127 low dose tid + SOC
Study NCT04032795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium barbarum polysaccharide
Description: Experimental group takes Lycium barbarum polysaccharide (LBP) tablet (300mg/day)for 6 weeks
Study NCT04032795 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-controlled group take he placebo capsules that are identical in shape, color, and taste to LBP tablet.
Study NCT03331263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate
Description: 2% CHG
Study NCT03671655 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent
Description: Drug eluting stent which are nitinol stent coated with Paclitaxel drug
Study NCT03671655 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bare metal stent
Description: Bare metal stent is Nitinol alloy self expandable stent. Other Names: Bare metal stent Nitinol stent SMART Stent Viabahn stent
Study NCT04127877 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICAS
Description: Electric regional bio impedance device
Study NCT03937544 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T CELLS
Description: CD19 CAR-T cells will be administered after completion of the chemotherapy.
Study NCT03937544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients will receive lymphodepleting chemotherapies consisting Cyclophosphamide 250mg/m2/day IV(Day -5, Day -4, Day -3 ).
Study NCT03937544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients will receive lymphodepleting chemotherapies consisting of Fludarabine 25mg/m2/day IV (Day -5, Day -4, Day -3 ).
Study NCT00594893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini Incision Approach
Description: Mini Incision Approach
Study NCT00594893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Incision Approach
Description: 2 Incision Approach
Study NCT02542397 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Testing
Description: Pharmacogenomic test results to guide drug/dose modifications
Study NCT02726789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REP 2139-Ca
Description: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
Study NCT02726789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon
Description: immunotherapy
Study NCT02726789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: local generic entecavir
Study NCT05868681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delos instrument (computerized balance board)
Description: Proprioceptive training using Delos instrument (computerized balance board).~Static and dynamic evaluation through Delos with the Riva method; Physiatric visit; Clinical scores (AOFAs); Functional scores (SPPB); SF12 satisfaction.
Study NCT01589419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: veliparib
Description: see arm description
Study NCT01589419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: see arm description
Study NCT01589419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: see arm description
Study NCT03106883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affective training
Description: 3 sessions of active training using affective faces to modify the negative attention bias in depression
Study NCT03106883 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham training
Description: 3 sessions of sham attention training using non-affective stimuli
Study NCT02554045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks